Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer

Zahida Qamri, Anju Preet, Mohd W. Nasser, Caroline E. Bass, Gustavo Leone, Sanford H. Barsky, Ramesh K. Ganju

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Cannabinoids have been reported to possess antitumorogenic activity.Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.W e have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.We have also observed that the breast cancer cell lines MDA-MB231, MDAMB231-luc, and MDA-MB468 express CB1 and CB2 receptors. Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.T hese results were confirmed in vivo in various mouse model systems.Mice treated with JWH-133 or WIN-55,212-2 showed a 40% to 50% reduction in tumor growth and a 65% to 80% reduction in lung metastasis.These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, respectively, suggesting involvement of CB1 and CB2 receptors.In addition, the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system. Upon further elucidation, we observed that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/ prostaglandin E2 signaling pathways and induction of apoptosis.These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis.

Original languageEnglish (US)
Pages (from-to)3117-3129
Number of pages13
JournalMolecular cancer therapeutics
Volume8
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Artificial Receptors
Cannabinoid Receptor Agonists
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Breast Neoplasms
Neoplasm Metastasis
Growth
Neoplasms
Cannabinoids
Oncogene Proteins
Cyclooxygenase 2
Human Mammary Glands
Dinoprostone
Transgenic Mice
Cell Movement
Breast
Cell Proliferation
Apoptosis
Cell Line
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. / Qamri, Zahida; Preet, Anju; Nasser, Mohd W.; Bass, Caroline E.; Leone, Gustavo; Barsky, Sanford H.; Ganju, Ramesh K.

In: Molecular cancer therapeutics, Vol. 8, No. 11, 01.11.2009, p. 3117-3129.

Research output: Contribution to journalArticle

Qamri, Zahida ; Preet, Anju ; Nasser, Mohd W. ; Bass, Caroline E. ; Leone, Gustavo ; Barsky, Sanford H. ; Ganju, Ramesh K. / Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. In: Molecular cancer therapeutics. 2009 ; Vol. 8, No. 11. pp. 3117-3129.
@article{dd8b2cc1c66748178ed0b143350cb1f8,
title = "Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer",
abstract = "Cannabinoids have been reported to possess antitumorogenic activity.Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.W e have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.We have also observed that the breast cancer cell lines MDA-MB231, MDAMB231-luc, and MDA-MB468 express CB1 and CB2 receptors. Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.T hese results were confirmed in vivo in various mouse model systems.Mice treated with JWH-133 or WIN-55,212-2 showed a 40{\%} to 50{\%} reduction in tumor growth and a 65{\%} to 80{\%} reduction in lung metastasis.These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, respectively, suggesting involvement of CB1 and CB2 receptors.In addition, the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system. Upon further elucidation, we observed that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/ prostaglandin E2 signaling pathways and induction of apoptosis.These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis.",
author = "Zahida Qamri and Anju Preet and Nasser, {Mohd W.} and Bass, {Caroline E.} and Gustavo Leone and Barsky, {Sanford H.} and Ganju, {Ramesh K.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1158/1535-7163.MCT-09-0448",
language = "English (US)",
volume = "8",
pages = "3117--3129",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer

AU - Qamri, Zahida

AU - Preet, Anju

AU - Nasser, Mohd W.

AU - Bass, Caroline E.

AU - Leone, Gustavo

AU - Barsky, Sanford H.

AU - Ganju, Ramesh K.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Cannabinoids have been reported to possess antitumorogenic activity.Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.W e have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.We have also observed that the breast cancer cell lines MDA-MB231, MDAMB231-luc, and MDA-MB468 express CB1 and CB2 receptors. Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.T hese results were confirmed in vivo in various mouse model systems.Mice treated with JWH-133 or WIN-55,212-2 showed a 40% to 50% reduction in tumor growth and a 65% to 80% reduction in lung metastasis.These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, respectively, suggesting involvement of CB1 and CB2 receptors.In addition, the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system. Upon further elucidation, we observed that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/ prostaglandin E2 signaling pathways and induction of apoptosis.These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis.

AB - Cannabinoids have been reported to possess antitumorogenic activity.Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis.W e have shown that the cannabinoid receptors CB1 and CB2 are overexpressed in primary human breast tumors compared with normal breast tissue.We have also observed that the breast cancer cell lines MDA-MB231, MDAMB231-luc, and MDA-MB468 express CB1 and CB2 receptors. Furthermore, we have shown that the CB2 synthetic agonist JWH-133 and the CB1 and CB2 agonist WIN-55,212-2 inhibit cell proliferation and migration under in vitro conditions.T hese results were confirmed in vivo in various mouse model systems.Mice treated with JWH-133 or WIN-55,212-2 showed a 40% to 50% reduction in tumor growth and a 65% to 80% reduction in lung metastasis.These effects were reversed by CB1 and CB2 antagonists AM 251 and SR144528, respectively, suggesting involvement of CB1 and CB2 receptors.In addition, the CB2 agonist JWH-133 was shown to delay and reduce mammary gland tumors in the polyoma middle T oncoprotein (PyMT) transgenic mouse model system. Upon further elucidation, we observed that JWH-133 and WIN-55,212-2 mediate the breast tumor-suppressive effects via a coordinated regulation of cyclooxygenase-2/ prostaglandin E2 signaling pathways and induction of apoptosis.These results indicate that CB1 and CB2 receptors could be used to develop novel therapeutic strategies against breast cancer growth and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=70949091684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70949091684&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-0448

DO - 10.1158/1535-7163.MCT-09-0448

M3 - Article

C2 - 19887554

AN - SCOPUS:70949091684

VL - 8

SP - 3117

EP - 3129

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -